Biology Reference
In-Depth Information
with in vitro regulation of eIF2 alpha phos-
phorylation. J Virol 77:4626-4634
88. Orvedahl A, Alexander D, Talloczy Z, Sun Q,
Wei Y, Zhang W, Burns D, Leib DA, Levine B
(2007) HSV-1 ICP34.5 confers neuroviru-
lence by targeting the Beclin 1 autophagy
protein. Cell Host Microbe 1:23-35
89. Alexander DE, Ward SL, Mizushima N,
Levine B, Leib DA (2007) Analysis of the role
of autophagy in replication of herpes simplex
virus in cell culture. J Virol 81:12128-12134
90. Rampling R, Cruickshank G, Papanastassiou
V, Nicoll J, Hadley D, Brennan D, Petty R,
MacLean A, Harland J, McKie E et al (2000)
Toxicity evaluation of replication-competent
herpes simplex virus (ICP34.5 null mutant
1716) in patients with recurrent malignant
glioma. Gene Ther 7:859-866
91. Detta A, Harland J, Hanif I, Brown SM,
Cruickshank G (2003) Proliferative activity
and in vitro replication of HSV1716 in human
metastatic brain tumours. J Gene Med 5:
681-689
92. Holman HA, MacLean AR (2008)
Neurovirulent factor ICP34.5 uniquely
expressed in the herpes simplex virus type 1
Delta gamma 1 34.5 mutant 1716. J Neurovirol
14:28-40
93. Hu JC, Coffi n RS, Davis CJ, Graham NJ,
Groves N, Guest PJ, Harrington KJ, James
ND, Love CA, McNeish I et al (2006) A
phase I study of OncoVEXGM-CSF, a
second-generation oncolytic herpes simplex
virus expressing granulocyte macrophage
colony-stimulating factor. Clin Cancer Res
12:6737-6747
94. Kohno SI, Luo C, Nawa A, Fujimoto Y,
Watanabe D, Goshima F, Tsurumi T,
Nishiyama Y (2007) Oncolytic virotherapy
with an HSV amplicon vector expressing
granulocyte-macrophage colony-stimulating
factor using the replication-competent HSV
type 1 mutant HF10 as a helper virus. Cancer
Gene Ther 14:918-926
95. Nagano S, Perentes JY, Jain RK, Boucher Y
(2008) Cancer cell death enhances the pene-
tration and effi cacy of oncolytic herpes simplex
virus in tumors. Cancer Res 68:3795-3802
96. Guffey MB, Parker JN, Luckett WS Jr,
Gillespie GY, Meleth S, Whitley RJ, Markert
JM (2007) Engineered herpes simplex virus
expressing bacterial cytosine deaminase for
experimental therapy of brain tumors. Cancer
Gene Ther 14:45-56
97. Currier MA, Gillespie RA, Sawtell NM,
Mahller YY, Stroup G, Collins MH, Kambara
H, Chiocca EA, Cripe TP (2008) Effi cacy and
safety of the oncolytic herpes simplex virus
rRp450 alone and combined with cyclophos-
phamide. Mol Ther 16:879-885
98. Fulci G, Breymann L, Gianni D, Kurozomi K,
Rhee SS, Yu J, Kaur B, Louis DN, Weissleder
R, Caligiuri MA et al (2006) Cyclophosphamide
enhances glioma virotherapy by inhibiting
innate immune responses. Proc Natl Acad Sci
USA 103:12873-12878
99. Aghi M, Chou TC, Suling K, Breakefi eld XO,
Chiocca EA (1999) Multimodal cancer treat-
ment mediated by a replicating oncolytic virus
that delivers the oxazaphosphorine/rat cyto-
chrome P450 2B1 and ganciclovir/herpes
simplex virus thymidine kinase gene therapies.
Cancer Res 59:3861-3865
100. Patterson AV, Saunders MP, Greco O (2003)
Prodrugs in genetic chemoradiotherapy. Curr
Pharm Des 9:2131-2154
101. Lazear E, Carfi A, Whitbeck JC, Cairns TM,
Krummenacher C, Cohen GH, Eisenberg RJ
(2008) Engineered disulfi de bonds in herpes
simplex virus type 1 gD separate receptor
binding from fusion initiation and viral entry.
J Virol 82:700-709
102. Stiles KM, Milne RS, Cohen GH, Eisenberg
RJ, Krummenacher C (2008) The herpes
simplex virus receptor nectin-1 is down-
regulated after trans-interaction with glyco-
protein D. Virology 373:98-111
103. Kamiyama H, Zhou G, Roizman B (2006)
Herpes simplex virus 1 recombinant virions
exhibiting the amino terminal fragment of
urokinase-type plasminogen activator can
enter cells via the cognate receptor. Gene
Ther 13:621-629
104. Zhou G, Ye GJ, Debinski W, Roizman B
(2002) Engineered herpes simplex virus 1 is
dependent on IL13Ralpha 2 receptor for cell
entry and independent of glycoprotein D
receptor interaction. Proc Natl Acad Sci USA
99:15124-15129
105. Conner J, Braidwood L, Brown SM (2008) A
strategy for systemic delivery of the oncolytic
herpes virus HSV1716: redirected tropism by
antibody-binding sites incorporated on the
virion surface as a glycoprotein D fusion pro-
tein. Gene Ther 15:1579-1592
106. Menotti L, Cerretani A, Hengel H,
Campadelli-Fiume G (2008) Construction of
a fully retargeted herpes simplex virus 1
recombinant capable of entering cells solely
via human epidermal growth factor receptor
2. J Virol 82:10153-10161
107. Glass M, Soling A, Messerle M (2008) Tumor-
specifi c activity of cellular regulatory elements
is down-regulated upon insertion into the her-
pes simplex virus genome. J Neurovirol 14:
522-535
Search WWH ::
Custom Search